Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Onco-Innovations Ltd. ( (TSE:ONCO) ) has issued an announcement.
Onco-Innovations has executed an engagement agreement with RDI Partners and created a wholly owned Australian subsidiary, Onco-Innovations AU Pty. Ltd., to support its planned Phase I clinical development in Australia. The structure is intended to leverage Australia’s streamlined early-phase trial environment and potential R&D tax incentives while strengthening regulatory compliance, financial governance, and scalable infrastructure for future global expansion.
The company also entered into a new online marketing engagement with MCS Market Communication Service GmbH, paying EUR 213,000 for digital campaigns and analytics through July 2026 or until budget exhaustion. This fixed-fee arrangement, not linked to market performance or securities compensation, aims to enhance Onco-Innovations’ market visibility as it approaches first-in-human trials in Australia.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian oncology-focused company dedicated to cancer research and treatment. It has secured an exclusive worldwide license to patented technology targeting solid tumours, positioning it as a developer of innovative therapeutic solutions in the global oncology market.
Average Trading Volume: 28,266
Technical Sentiment Signal: Sell
Current Market Cap: C$84.6M
For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.